Limbic Limited

Limbic Limited, also known as Limbic AI, is a UK-based company specializing in advanced clinical AI solutions that enhance mental healthcare delivery through automation and support for patients and providers. Founded in 2017 and headquartered in London, UK, Limbic Limited develops innovative AI tools for mental health treatment. The company was co-founded by Ross Harper and Sebastiaan de Vries. In March 2024, Limbic raised USD 14 mn in Series A funding led by Khosla Ventures, with participation from Gaingels and Illusian Group.

This funding marks the latest in a series of three deals for the company, which has a strategic focus on investing in its AI-driven mental health services. Limbic offers advanced clinical AI solutions designed to enhance mental healthcare delivery. Their core products include Limbic Access and Limbic Care, which integrate seamlessly into existing healthcare systems to facilitate patient intake, assessment, and ongoing support. Limbic Access serves as an AI assistant that automates the onboarding process for patients, streamlining intake pathways via web and mobile interfaces, while Limbic Care functions as an on-demand AI companion, providing Cognitive Behavioral Therapy (CBT) through generative chat.

These products aim to address the growing demand for behavioral health services by increasing access and efficiency in care delivery. Limbic's solutions are utilized by health plans and care providers across various geographical markets, including the United States and the United Kingdom, targeting over 1. 6 billion individuals in need of mental health support. Limbic generates revenue by providing subscription-based access to its clinical AI technologies tailored for healthcare providers and health plans.

The company's transaction structure primarily focuses on B2B partnerships, where clients subscribe to use Limbic's platform for enhanced patient management and care delivery. Clients benefit from the implementation of Limbic Access and Limbic Care, which enable improved patient intake processes and treatment outcomes. Specific pricing plans for these services are determined based on the scale and needs of the client organization, ensuring customization and alignment with the clients’ operational frameworks. The revenue model is reinforced by Limbic’s position as the only Class II medical device for AI-enabled diagnostic support, further solidifying its value proposition in the healthcare market.

In March 2024, Limbic raised USD 14 mn in Series A funding to expand its clinical mental health AI services to the US market. The company plans to leverage this funding to enhance its product offerings and develop new solutions that cater specifically to the needs of healthcare providers in the US. Additionally, Limbic aims to explore other international markets for expansion, enabling broader access to their AI-driven mental health solutions, thereby addressing the increasing demand for mental health support globally.